Mongolia Medical APIs Overseas Market Analysis Report

Mongolia's medical API market is characterized by 100% import dependency, with total imports reaching approximately USD 280-320 million in 2025 and Chinese supplies accounting for over 65%. In H1 2026, the MNT depreciated approximately 6.2% against the USD, driving up import costs. ⚠ Currency risk is intensifying, though the RMB settlement ratio has risen to 38%, partially easing pressure. There is no domestic API synthesis capacity; annual demand is growing at roughly 7-9%, and the market is highly concentrated in Ulaanbaatar.

• 📊 Import dependency: ≈100% (no domestic API capacity)
• 🇨🇳 Chinese supply share: 65%-70%
• 💰 MNT/USD (June 2026): approx. 3,620 MNT/USD Depreciation 6.2%
• 📈 Annual demand growth: 7%-9%

Sources: National Statistics Office of Mongolia, Bank of Mongolia Monetary Policy Report (June 2026), General Administration of Customs of China (January-June 2026)

Mongolia's annual medical API demand is approximately 3,500-4,000 tons, covering antibiotics, vitamins, antipyretic analgesics, and other categories, with 100% reliance on imports. Supply is highly concentrated, with China, India, and Russia together accounting for over 88% of import volume. Ulaanbaatar consumes roughly 78% of the nation's medical APIs, with the remainder distributed to Darkhan, Erdenet, and other cities.

Sources: Mongolian Customs General Administration, National Statistics Office of Mongolia Trade Data (Updated June 2026)

As the world's largest API producer, China maintained steady export growth to Mongolia in H1 2026. Key export categories—antibiotic intermediates, vitamins, and antipyretic analgesic raw materials—accounted for 72% of total exports to Mongolia. Domestic API capacity utilization remained at 78%-82%, with overall price stability.

• 🏭 API capacity utilization: 78%-82% (Q2 2026)
• 📦 API exports to Mongolia (H1): approx. USD 98 million
• 💊 Antibiotic export share: 45%
• 🚚 Primary port: Erenhot (85%+ of exports to Mongolia)

Sources: General Administration of Customs of China Import/Export Data (January-June 2026), China Chamber of Commerce for Import & Export of Medicines & Health Products

Although modest in size, Mongolia's medical API market is experiencing steady growth, with H1 2026 imports reaching approximately USD 152 million. Ulaanbaatar hosts the main importers and formulation enterprises, with CIF prices carrying a premium of 15%-25% over Chinese ex-factory prices. India and Russia are intensifying their supply efforts, but China retains absolute dominance.

Sources: Mongolian Customs General Administration Import Statistics (June 2026), National Statistics Office of Mongolia

Antibiotic APIs dominate Mongolia's medical API imports at approximately 45%, followed by vitamins and antipyretic analgesics. Cardiovascular APIs show the fastest demand growth at 12%-15% annually, reflecting Mongolia's rising chronic disease burden. Prices across all categories are notably affected by international API market fluctuations.

Sources: Mongolian Customs General Administration Commodity Classification Data (June 2026), Ministry of Health of Mongolia Pharmaceutical Catalogue

Approximately 15-20 domestic formulation enterprises in Mongolia are concentrated mainly in Ulaanbaatar, focusing on repackaging and simple formulations without any API synthesis capability. In H1 2026, domestic formulation output was approximately 1,200 tons (finished drugs), covering roughly 30% of domestic finished drug demand; the remaining 70% relies on finished drug imports. All APIs are fully imported.

• 🏭 Domestic formulation enterprises: 17 (15 in Ulaanbaatar)
• 📦 Domestic formulation output (H1): approx. 1,200 tons
• 📊 Finished drug self-sufficiency: approx. 30%
• 🔗 API self-sufficiency: 0% (fully import-dependent)

Sources: Ministry of Health of Mongolia, Mongolian Drug Administration Annual Report (2025), carried forward (no update as of July 2026)

A price spread of 15%-25% exists between Chinese ex-factory API prices and Mongolian CIF prices, primarily driven by cross-border transportation, port customs clearance, and intermediary markups. Road transport from Erenhot to Ulaanbaatar accounts for approximately 6%-9% of total landed cost. RMB settlement can reduce foreign exchange losses by approximately 2-3 percentage points.

Sources: China Chamber of Commerce for Import & Export of Medicines & Health Products Price Monitoring (June 2026), Mongolia Importer Quotations Composite

Mongolia's GDP growth in 2026 is expected to remain at 5.2%-5.8%, with mining export revenues (copper, coal) supporting medical import purchasing power. The MNT continues to face depreciation pressure, but cross-border RMB settlement has risen to 38%, effectively reducing foreign exchange risk. The pharmaceutical import tariff remains at 5%, with no major trade barriers at present.

Sources: World Bank Mongolia Economic Update (April 2026), Bank of Mongolia, Asian Development Bank Mongolia Country Report (May 2026)

Key risks include continuous MNT depreciation driving up import costs and occasional congestion at the China-Mongolia border port affecting supply chain timelines. On the opportunity side, the Mongolian government is advancing its domestic pharmaceutical industry development plan, offering tax incentives for API importers; in the ongoing China-Mongolia FTA upgrade negotiations, pharmaceutical tariffs are expected to be further reduced.

• ⚠️ Currency risk: MNT annual depreciation may reach 6%-8%
• 🚧 Supply chain risk: Occasional congestion at Erenhot port (3 times in Q1 2026)
• ✅ Opportunity: Localization substitution policy — Mongolian government encourages API import substitution
• 🤝 Opportunity: China-Mongolia FTA upgrade — pharmaceutical tariff may be reduced to 3%

Sources: Government of Mongolia 2026 Pharmaceutical Industry Development Plan, Erenhot Customs Clearance Data (Q1 2026), China-Mongolia Economic and Trade Cooperation Joint Statement